Join the DDA or

Esmya licence suspension

Serious liver injury link identified

March 19th 2020

Tagged: MHRA alert

By MHRA

Healthcare professionals are asked to contact patients taking Esmya (ulipristal acetate) for uterine fibroids as soon as possible to stop treatment and advise on alternatives.

Recent users should be told to seek immediate medical attention if they develop signs and symptoms of liver injury (nausea, vomiting, malaise, right hypochondrial pain, anorexia, asthenia or jaundice).

In addition:

  • No patients should be started on Esmya
  • Practices should perform liver function tests 2–4 weeks after stopping Esmya

Please note there are no concerns with emergency contraceptive ellaOne (ulipristal acetate 30mg single dose) at this time